Frontiers in Anti-Cancer Drug Discovery

Volume: 2

Indexed in: Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Strategies for Improving the Systemic Delivery of Oncolytic Adenoviruses and Plasmids: Potential Application of Non-Viral Carriers

Pp. 190-225 (36)

Mireia Agirre, Jon Zarate, Gustavo Puras, Luis A. Rojas, Ramon Alemany and José L. Pedraz

Abstract

Virotherapy is the use of oncolytic or tumor-selective viruses to treat cancer. The replication of the virus inside a tumor can debulk the tumor mass and simultaneously, revert the immune suppressor environment that causes the immune escape of tumor cells. This therapeutic approach was discovered ten years ago but it has been renewed in the last decade with designed viruses. Adenovirus (Ad) is a nonenveloped DNA virus that infects broadly tumor cells and it has been frequently used in cancer gene therapy and virotherapy. A very high level of tumor-specific replication has been obtained with adenoviruses by replacing early viral gene promoters with tumorselective promoters. However, the complex Ad capsid interactions with blood proteins and cells and, also with liver and spleen macrophages result in rapid blood clearance and the prevention of systemic tumor targeting. To settle these problems, a new field is emerging where an oncolytic Ad genome is complexed to non-viral vectors to target tumors.

Keywords:

Oncolytic viruses, non-viral vectors, oncolytic adenoviral genome, modified adenoviruses, tumor targeting.

Affiliation:

Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, 01006, Vitoria-Gasteiz, Spain.